READ-GENE S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.98 PLN | +0.61% |
|
+4.40% | -14.14% |
| 05-14 | Read-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-12 | Read-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2022 | 7.24M 1.8M 2.47M | Sales 2023 | 10.15M 2.52M 3.46M | Capitalization | 68.38M 16.99M 23.29M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 0 | Net income 2023 | -1M -248K -341K | EV / Sales 2022 | 3.88 x |
| Net cash position 2022 | 2.32M 576K 790K | Net Debt 2023 | 1.87M 464K 637K | EV / Sales 2023 | 6.92 x |
| P/E ratio 2022 |
143
x | P/E ratio 2023 |
-50.8
x | Employees | 21 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 24.77% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.61% | ||
| 1 week | +4.40% | ||
| Current month | +5.06% | ||
| 1 month | +5.51% | ||
| 3 months | -6.04% | ||
| 6 months | -14.14% | ||
| Current year | -14.14% |
1 week
4.62
4.98
1 month
4.494.98
Current year
4.306.20
1 year
2.707.80
3 years
1.897.80
5 years
0.587.80
10 years
0.387.80
| Managers | Title | Age | Since |
|---|---|---|---|
Jan Lubinski
CEO | Chief Executive Officer | - | - |
| Director of Finance/CFO | - | - | |
Karolina Kleszcz
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
Tomasz Huzarski
CHM | Chairman | - | - |
Jacek Gronwald
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-28 | 4.98 | +0.61% | 68 |
| 24-06-27 | 4.95 | 0.00% | 472 |
| 24-06-26 | 4.95 | +1.02% | 991 |
| 24-06-25 | 4.9 | +2.51% | 210 |
| 24-06-24 | 4.78 | +0.21% | 211 |
End-of-day quote Warsaw S.E., June 27, 2024
More quotes
Read-Gene SA is a Poland-based company active in the biotechnology sector. It is focused on technologies which aim is to detect, prevent and treat malignant tumors. The Company specializes in three fields: chemoprevention, clinical trials and genetic testing. It offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The Company operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.14% | 14.6M | |
| -42.89% | 7.8B | |
| +6.77% | 3.53B | |
| -1.35% | 2.24B | |
| -27.06% | 1.84B | |
| -21.23% | 1.66B | |
| +9.31% | 951M | |
| +29.42% | 811M | |
| -12.66% | 670M | |
| -26.12% | 533M |
- Stock Market
- Equities
- RDG Stock
